6.83
-0.27
(-3.87%)
As of 12:57:17 PM EST. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Alex Nichols Ph.D. | Chief Strategy & Operations Officer | 504.44k | -- | 1985 |
| Mr. Ronald H. W. Cooper | Chief Executive Officer & Director | -- | -- | 1963 |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer | 341.75k | -- | 1972 |
| Mr. John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board | -- | -- | -- |
| Mr. David Ryan Daws | CFO & Head of Business Development | -- | -- | 1974 |
| Ms. Joan Connolly | Chief Technology Officer | -- | -- | -- |
| Mr. Lee G. Giguere | Chief Legal Officer & Corporate Secretary | -- | -- | 1981 |
| Ms. Sharon Tan | VP of Project Management & Head of Program Management | -- | -- | -- |
| Dr. Raj Pruthi F.A.C.S., M.D., M.H.A. | Chief Medical Officer | -- | -- | -- |
| Mr. Paul Erickson | Non-Executive Director | -- | -- | -- |
enGene Holdings Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 31
Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). The company is based in Montreal, Canada.
Corporate Governance
enGene Holdings Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
December 20, 2024 at 3:33 AM UTC
enGene Holdings Inc. Earnings Date
Recent Events
November 19, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
Related Tickers
CALC CalciMedica, Inc.
2.5400
0.00%
ATXS Astria Therapeutics, Inc.
7.94
+5.94%
MAR.F Maravai LifeSciences Holdings, Inc.
4.8800
+2.52%
296.MU CytoDyn Inc
0.1990
+9.94%
TRDA Entrada Therapeutics, Inc.
13.78
+3.07%
OCSAW Oculis Holding AG
11.31
-1.67%
OCS Oculis Holding AG
22.78
+1.92%
LXEO Lexeo Therapeutics, Inc.
5.58
+6.29%
SLN Silence Therapeutics plc
5.35
+1.81%
LENZ LENZ Therapeutics, Inc.
27.40
+7.54%